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Introduction
Alcohol has been shown to have multiple effects on 
the immune system. However, the pathogenesis of
alcoholic liver disease is not fully understood. It is
postulated that chronic alcohol consumption may be
associated with increased proinflammatory cytokines in
the serum and deranged balance between proinflam-
matory cytokine and anti-inflammatory cytokines.1–3
Interleukin (IL)-12 is a proinflammatory cytokine
produced by antigen-presenting cells upon stimula-
tion by various pathogens. This cytokine has been
shown to have direct effects on natural killer cells and
T cells, and primes T helper 1 response.4,5 Laso et al
have demonstrated that serum IL-12 levels are
increased in chronic alcoholism, with or without alco-
holic liver disease.6 It has also been shown that serum
IL-12 levels return to within normal limits 1 year
after cessation of alcohol consumption. The clinical
significance of serum IL-12 in the diagnosis of alco-
holism and various alcoholic liver diseases has yet to
be elucidated. The purpose of this study was to
explore the relationship between IL-12 serum levels
and the different stages of alcoholic liver disease. The
influence of abstinence from alcohol on serum IL-12
level was also evaluated.
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Methods
Subjects
Ninety-four patients with alcoholic liver disease and
35 healthy adults without alcohol consumption were
included in this study. All of the alcoholic patients had
consumed, on average, at least 50 g of ethanol per day
for more than 5 years. Of them, 17 were diagnosed to
have alcoholic steatosis based on the findings of liver
pathology and abdominal sonography. Their serum ala-
nine aminotransferase (ALT) and/or aspartate amino-
transferase (AST) were less than twice the upper limit
of normal. Thirty-seven patients had alcoholic hepatitis,
diagnosed by the characteristic liver pathological find-
ings of steatohepatitis, with or without fibrosis; how-
ever, they did not have any pathological or clinical
evidence of liver cirrhosis. Their serum ALT and/or
AST were more than twice the upper limit of normal.
The remaining 40 alcoholic patients were diagnosed to
have alcoholic cirrhosis. In 14 of them, alcoholic cir-
rhosis was verified by the pathological findings of liver
biopsy. In the other 26 patients, liver biopsy was not
done due to the presence of coagulopathy, ascites or
patient refusal; instead, alcoholic cirrhosis was diag-
nosed based on the typical clinical stigmata of cirrhosis,
including ascites, esophageal varices, hepatic enceph-
alopathy, hypoalbuminemia, and the presence of an
uneven liver surface, decreased hepatic size, collateral
circulation and splenomegaly on imaging studies. All of
the patients and controls were negative for serum hepa-
titis B surface antigen and anti-hepatitis C antibody, and
no autoimmune liver disease was found in any of them.
After enrolment, the patients were followed-up
every 3 months for a total of 9 months; serum IL-12
concentration was measured at each follow-up. Edu-
cation and abstinence from alcohol was advised to all
the patients. Careful interviews with patients and their
families, in addition to regular follow-up liver enzyme
tests, were done to determine if the patient had quit
alcohol drinking or not.
This study was approved by the institutional review
board of our hospital. All of the study subjects signed
informed consent forms.
Serum IL-12 levels were measured using a commer-
cial enzyme-linked immunosorbent assay (PeproTech
Inc., Rocky Hill, NJ, USA). The IL-12 detection range
of this kit is from 32 to 3,000 pg/mL. For the conven-
ience of statistical analysis, all undetectable IL-12 levels
(i.e. < 32 pg/mL) were recorded as being 32 pg/mL.
Statistical analysis
The data are expressed as mean ± standard deviation
unless otherwise noted. Comparisons of variables among
the different alcoholic liver disease groups and healthy
controls were carried out using ANOVA and Tukey’s
test. Multiple linear regression was applied to evaluate
the correlation between IL-12 and age, amount and
duration of alcohol drinking. Student’s t test was used
to compare serum IL-12 levels between the alcohol
abstinence group and the continuous alcohol intake
group at different time periods. For further confirma-
tion, repeated measures general linear model was
used to evaluate the sequential changes in IL-12 in the
abstinence and continuous alcohol drinking groups.
Receiver operating characteristic curve was applied to
select the best cut-off value of IL-12 for the discrimi-
nation of alcoholic liver disease. Statistical tests were
based on 2-tailed probability. A p value < 0.05 was con-
sidered significant. All analyses were performed using
SPSS version 13.0 (SPSS Inc., Chicago, IL, USA).
Results
The patients with alcoholic liver cirrhosis were older,
had a higher Child-Pugh score, higher volume of daily
alcohol intake, and longer duration of alcohol consu-
mption than the patients in the other groups (Table 1).
The patients with alcoholic hepatitis had higher serum
ALT, AST and γ-glutamyltransferase levels than those
in the other groups. Serum IL-12 levels were highest 
in the alcoholic hepatitis group (163.1 ± 57.8 pg/
mL), followed by the alcoholic liver cirrhosis group
(110.5 ± 41.6 pg/mL) and the alcoholic steatosis
group (74.4 ± 26.2 pg/mL; p < 0.02 between groups)
(Table 1). All of these 3 groups had higher serum IL-
12 levels than the control group (39.3 ± 8.3 pg/mL;
p < 0.02). Furthermore, there was no association
between IL-12 levels and age, average daily amount of
alcohol consumption, and duration of alcohol con-
sumption (p = 0.962, 0.155 and 0.084, respectively).
Ten of the steatosis patients, 17 of the hepatitis
patients, and 30 of the cirrhosis patients were noted
to have abstained from alcohol during the follow-up
period. The serum IL-12 levels between the abstinence
and non-abstinence groups at the 9th month are shown
in Figure 1. Among the patients who abstained from
alcohol, there was no difference in serum IL-12 levels
between the control and steatosis patients. However,
the serum IL-12 levels of the hepatitis and cirrhosis
groups were still higher than in the control group 
(p < 0.001 and p = 0.001, respectively). The patients
who continued to consume alcohol had higher serum
IL-12 levels than those who had abstained from alco-
hol in the steatosis, hepatitis and cirrhosis groups
(Figure 1).
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Table 1. Clinical characteristics and serum interleukin-12 levels in controls and patients with alcoholic steatosis, alcoholic hepatitis
and alcoholic cirrhosis*
Controls (n = 35) Steatosis (n = 17) Hepatitis (n = 37) Cirrhosis (n = 40)
Age (yr) 44.4 ± 14.5 45.6 ± 15.9 46.4 ± 10.3 54.9 ± 9.6†
Sex (M/F) 21/14 11/6 26/11 31/9
ALT (U/L) 25.4 ± 7.2 64.2 ± 10.2 203.8 ± 112.2† 91.7 ± 76.2‡
AST (U/L) 27.7 ± 7.3 75.9 ± 12.8 272.2 ± 121.9† 125.7 ± 95.7‡
GGT (U/L) 35.6 ± 12.4 100.1 ± 76.9 134.2 ± 97.6† 92.3 ± 54.9‡
Alk-P (U/L) 61.9 ± 21.8 94.8 ± 29.1‡ 83.2 ± 33.8‡ 72.2 ± 21.5
Total bilirubin (mg/dL) 0.9 ± 0.3 0.8 ± 0.3 1.1 ± 0.7 1.5 ± 1.0‡
Child-Pugh score – 5.0 ± 0.0 5.1 ± 0.3 7.3 ± 2.5†
Daily alcohol intake (g/d) – 58.1 ± 8.9 60.4 ± 11.3 68.0 ± 16.2†
Duration of alcohol intake (yr) – 6.5 ± 1.3 10.2 ± 4.4 17.0 ± 5.1†
Interleukin-12 (pg/mL) 39.3 ± 8.3 74.4 ± 26.2‡ 163.1 ± 57.8† 110.5 ± 41.6‡
*Data presented as mean ± standard deviation or n; †p < 0.05 vs. the other 3 groups; ‡p < 0.05 vs. controls. ALT = alanine aminotransferase (normal range,
0–40 U/L); AST = aspartate aminotransferase (normal range, 5–45 U/L); GGT = g-glutamyltransferase (normal range, 8–60 U/L); Alk-P = alkaline phosphatase
(normal range, 10–100 U/L). Total bilirubin normal range = 0.2–1.6 mg/dL.
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Figure 1. Serum interleukin-12 levels in patients who abstained
from alcohol (white bars) and those who continued drinking (grey
bars) as measured at the 9-month follow-up. *p < 0.002 vs. con-
trol patients.
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Figure 2. Difference in interleukin-12 levels between patients who
continued drinking alcohol and those who abstained among the
patients with alcoholic hepatitis and cirrhosis. The patients who con-
tinued drinking had higher mean serum interleukin-12 levels than
those who abstained at the 3rd, 6th and 9th months of follow-up,
respectively (*†‡p<0.002). pa vs. b <0.001; pb vs. c <0.001.
If the hepatitis and cirrhosis groups were combined
into 1 group with significant alcoholic liver disease, the
patients who had abstained from alcohol had signifi-
cantly lower serum IL-12 levels than those who did not
abstain at the 3rd, 6th and 9th months (Figure 2). Fur-
thermore, the difference in IL-12 levels between the
alcohol non-abstinence and abstinence groups showed
an increasing trend with time, from 9.0 pg/mL (95%
confidence interval, –17.3–35.3) to 38.0 pg/mL
(17.1–58.9), 70.8 pg/mL (51.1–90.6), and 83.2 pg/
mL (61.1–105.3) at baseline, and the 3rd, 6th and 9th
months, respectively (Figure 2). In the abstinence
group, there was a significant reduction in IL-12 levels
from baseline to the 3rd month, and from the 3rd month
to the 6th month (p < 0.001), and a trend of IL-12
reduction from the 6th month to the 9th month (p =
0.055). In contrast, there was no significant consecutive
change in IL-12 levels in the non-abstinence group
(Figure 2).
Table 2 denotes the diagnostic sensitivity and speci-
ficity of IL-12 for alcoholic liver disease after choosing
the best cut-off value. IL-12 had good sensitivity and
specificity in the diagnosis of overall alcoholic liver dis-
ease, or alcoholic hepatitis and cirrhosis, at the cut-off
value of 54 pg/mL. However, IL-12 had relatively
poor sensitivity (76.5%) for the detection of alcoholic
steatosis. At the cut-off point of 94 pg/mL, IL-12
could differentiate alcoholic hepatitis from alcoholic
steatosis with good sensitivity (91.9%) and acceptable
specificity (82.3%) (Table 2).
Discussion
The present study showed that serum IL-12 levels were
elevated in patients with alcoholic steatosis, alcoholic
hepatitis, and alcoholic cirrhosis; patients with alcoholic
hepatitis had the highest serum IL-12 levels. Patients’
serum levels progressively decreased if they abstained
from alcohol. Most of our results are compatible with
Laso et al’s findings.6
In patients with chronic alcoholism without signifi-
cant liver disease, both pro- and anti-inflammatory
cytokines may be produced and maintain a subtle bal-
ance.2 However, when gut permeation is changed by
continuous alcohol intake, endotoxemia may develop.2
IL-12 can be produced by Kupffer cells upon stimula-
tion by endotoxin. IL-12 production may thereafter
outnumber the production of anti-inflammatory cy-
tokines, with the subsequent production of interferon-γ
and maintenance of T helper 1 immune response.7
Serum IL-12 then induces the expression of interferon-
γ in T cells and natural killer cells, which leads to 
macrophage activation and further inflammation.8,9
On the other hand, progression to alcoholic cirrho-
sis requires the activation of other fibrogenic cytokines
such as transforming growth factor-β. It has been 
shown that transforming growth factor-β can inhibit the
production of IL-12.10 This may partly explain why
people with alcoholic cirrhosis had lower serum IL-12
levels than alcoholic hepatitis patients.
In this study, serum IL-12 levels were found to
decrease after alcohol abstinence in patients with alco-
holic hepatitis and cirrhosis. But these levels were still
higher than those of controls. In contrast, Laso et al
demonstrated that serum IL-12 levels returned to within
normal limits after 1 year of alcohol abstinence.6 Al-
though our study had a similar finding, we only fol-
lowed serum IL-12 levels to the 9th month after alcohol
abstinence. It is probable that serum IL-12 levels would
have decreased to normal range if we had followed-up
our patients for longer.
Patients with chronic alcohol consumption may hes-
itate to admit their habit, and it is difficult for us to
determine whether or not patients abstained from alco-
hol following our advice and education. The clinical sig-
nificance of decreasing IL-12 levels after abstinence may
help us to evaluate the real alcohol drinking status of
patients, which would be helpful in the management of
patients and prediction of prognosis.
We found that serum IL-12 levels decreased to nor-
mal range in patients with alcoholic steatosis after alco-
hol abstinence. This may be a reflection of the reversible
nature of alcoholic fatty liver itself. It is well known that
the appearance of steatohepatitis is an important rate-
limiting step in the development of progressive alco-
holic liver disease. When cirrhosis has developed, alcohol
abstinence may not halt the progression of cirrhosis.1
Since the clinical manifestations of alcoholic hepatitis
and alcoholic steatosis are similar, it is very difficult to
differentiate between these 2 entities without confirma-
tion from liver pathology. In this study, if we chose 94.0
pg/mL as the cut-off point, the discriminative sensitiv-
ity and specificity between these 2 alcoholic liver dis-
eases were more than 82% (Table 2). To the best of our
knowledge, there is no other biomarker with such diag-
nostic accuracy. IL-12 has the potential to discriminate
steatosis from hepatitis. However, further large-scale
studies are warranted to establish the true diagnostic
role of IL-12 in this setting.
Since the discovery of IL-12, much has been learned
about its biological activity and signal transduction
pathway. A better understanding of the pathogenesis of
alcoholic liver disease and the biological activities of IL-
12 will lead to an exploration of agents for the treat-
ment of alcoholic liver disease. Inhibitors of IL-12
production or activity have potential for the treatment
of alcoholic liver disease.11 These agents act through the
inhibition of nuclear factor-κB, modulating intracellular
cAMP, post-translational inhibition of IL-12 produc-
tion or inhibition of IL-12 signal transduction path-
way.12,13 Of these, pentoxifylline has been used in the
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Table 2. Diagnostic value of interleukin-12 in alcoholic liver disease
Best cut-off value of
IL-12 (pg/mL)
Sensitivity (%) Specificity (%)
All ALD vs. controls 54.0 90.4 97.1
Hepatitis or cirrhosis vs. controls 54.0 93.5 97.1
Steatosis vs. controls 54.0 76.5 97.1
Hepatitis vs. steatosis 94.0 91.9 82.4
Hepatitis vs. cirrhosis 128.5 81.1 67.5
IL = interleukin; ALD = alcoholic liver disease.
treatment of severe acute alcoholic hepatitis with
promising results.14,15
Alcoholic and non-alcoholic steatohepatitis (NASH)
share similar clinical manifestations and pathological
features. Patients with NASH have dysregulated cy-
tokine metabolism similar to but less pronounced than
the abnormalities documented in alcoholic hepatitis.1
Further studies are necessary to evaluate the role of
cytokines in the pathogenesis of NASH.
In conclusion, our study demonstrated that serum
IL-12 levels reflect the different stages of alcoholic liver
disease and can represent the status of continuous
alcohol consumption. It has the potential to become
a biomarker of alcoholic liver disease.
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